Toll Free: 1-888-928-9744

Lupus Nephritis - Pipeline Review, H2 2016

Published: Sep, 2016 | Pages: 142 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Lupus Nephritis - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Lupus Nephritis - Pipeline Review, H2 2016', provides an overview of the Lupus Nephritis pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Lupus Nephritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Lupus Nephritis and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Lupus Nephritis
- The report reviews pipeline therapeutics for Lupus Nephritis by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Lupus Nephritis therapeutics and enlists all their major and minor projects
- The report assesses Lupus Nephritis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Lupus Nephritis

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Lupus Nephritis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Lupus Nephritis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Lupus Nephritis Overview 9 Therapeutics Development 10 Pipeline Products for Lupus Nephritis - Overview 10 Pipeline Products for Lupus Nephritis - Comparative Analysis 11 Lupus Nephritis - Therapeutics under Development by Companies 12 Lupus Nephritis - Therapeutics under Investigation by Universities/Institutes 14 Lupus Nephritis - Pipeline Products Glance 15 Late Stage Products 15 Clinical Stage Products 16 Early Stage Products 17 Lupus Nephritis - Products under Development by Companies 18 Lupus Nephritis - Products under Investigation by Universities/Institutes 20 Lupus Nephritis - Companies Involved in Therapeutics Development 21 AbbVie Inc 21 Asahi Kasei Pharma Corp. 22 Astellas Pharma Inc. 23 Aurinia Pharmaceuticals Inc 24 Azano Pharmaceuticals Inc. 25 Boehringer Ingelheim GmbH 26 Bristol-Myers Squibb Company 27 Deltanoid Pharmaceuticals Inc. 28 F. Hoffmann-La Roche Ltd. 29 GlaxoSmithKline Plc 30 HanAll Biopharma Co., Ltd. 31 Invion Limited 32 KPI Therapeutics, Inc. 33 MedImmune, LLC 34 Omeros Corporation 35 Ra Pharmaceuticals, Inc. 36 Resolve Therapeutics, LLC 37 Takeda Pharmaceutical Company Limited 38 TxCell SA 39 Lupus Nephritis - Therapeutics Assessment 40 Assessment by Monotherapy Products 40 Assessment by Target 41 Assessment by Mechanism of Action 43 Assessment by Route of Administration 45 Assessment by Molecule Type 47 Drug Profiles 49 abatacept - Drug Profile 49 Product Description 49 Mechanism Of Action 49 R&D Progress 49 anifrolumab - Drug Profile 54 Product Description 54 Mechanism Of Action 54 R&D Progress 54 belimumab - Drug Profile 56 Product Description 56 Mechanism Of Action 56 R&D Progress 56 BI-655064 - Drug Profile 62 Product Description 62 Mechanism Of Action 62 R&D Progress 62 BMS-986147 - Drug Profile 64 Product Description 64 Mechanism Of Action 64 R&D Progress 64 dalazatide - Drug Profile 65 Product Description 65 Mechanism Of Action 65 R&D Progress 65 DP-001 - Drug Profile 69 Product Description 69 Mechanism Of Action 69 R&D Progress 69 Drug to Antagonize Bradykinin Receptor B1 for Lupus Nephritis - Drug Profile 70 Product Description 70 Mechanism Of Action 70 R&D Progress 70 ENTX-DN - Drug Profile 71 Product Description 71 Mechanism Of Action 71 R&D Progress 71 HL-161 - Drug Profile 72 Product Description 72 Mechanism Of Action 72 R&D Progress 72 INV-103 - Drug Profile 73 Product Description 73 Mechanism Of Action 73 R&D Progress 73 ixazomib citrate - Drug Profile 76 Product Description 76 Mechanism Of Action 76 R&D Progress 76 mizoribine - Drug Profile 85 Product Description 85 Mechanism Of Action 85 R&D Progress 85 Monoclonal Antibody for Lupus Nephritis - Drug Profile 86 Product Description 86 Mechanism Of Action 86 R&D Progress 86 obinutuzumab - Drug Profile 87 Product Description 87 Mechanism Of Action 87 R&D Progress 87 OMS-721 - Drug Profile 94 Product Description 94 Mechanism Of Action 94 R&D Progress 94 P-Dex - Drug Profile 99 Product Description 99 Mechanism Of Action 99 R&D Progress 99 RA-101495 - Drug Profile 100 Product Description 100 Mechanism Of Action 100 R&D Progress 100 RO-5461111 - Drug Profile 102 Product Description 102 Mechanism Of Action 102 R&D Progress 102 RSLV-145 - Drug Profile 103 Product Description 103 Mechanism Of Action 103 R&D Progress 103 Stem Cell Therapy for Autoimmune Diseases - Drug Profile 104 Product Description 104 Mechanism Of Action 104 R&D Progress 104 Synthetic Peptide to Inhibit Complement C5 for Paroxysmal Nocturnal Hemoglobinuria, Atypical Hemolytic Uremic Syndrome and Autoimmune Disorders - Drug Profile 106 Product Description 106 Mechanism Of Action 106 R&D Progress 106 venetoclax - Drug Profile 107 Product Description 107 Mechanism Of Action 107 R&D Progress 107 voclosporin - Drug Profile 116 Product Description 116 Mechanism Of Action 116 R&D Progress 116 Y-175L - Drug Profile 123 Product Description 123 Mechanism Of Action 123 R&D Progress 123 Lupus Nephritis - Dormant Projects 124 Lupus Nephritis - Discontinued Products 126 Lupus Nephritis - Product Development Milestones 127 Featured News & Press Releases 127 Aug 15, 2016: Aurinia Pharmaceuticals Announces Voclosporin Meets Primary Endpoint in Phase IIB AURA-LV Study in Lupus Nephritis 127 Jun 28, 2016: Aurinia Announces 24 Week Remission Rates from the First Seven Patients in its Open Label AURION Study in Lupus Nephritis (LN) 129 Jun 10, 2016: Alliance for Children Therapeutics Presents Dalazatide Data Demonstrating Positive Response in Lupus 130 May 23, 2016: KPI Therapeutics to Present Updated Dalazatide Study Data in Lupus 131 May 12, 2016: Aurinia Announces Presentations at the European Renal Association - European Dialysis and Transplant Association Meeting 131 May 09, 2016: Aurinia Initiates First Clinical Study of Voclosporin for Japan 132 Apr 20, 2016: Patient Dosing Initiated for OMS721 Phase 2 Program in Renal Diseases 133 Mar 29, 2016: Aurinia Announces Result from Data and Safety Monitoring Board for Its Phase 2b Study in Lupus Nephritis - Study to Continue as Planned 134 Mar 02, 2016: Aurina Receives FDA Fast Track Designation for Voclosporin for the Treatment of Lupus Nephritis 135 Feb 08, 2016: Aurinia Announces Preliminary Topline Data From its Open Label Aurion Study in Lupus Nephritis 135 Feb 02, 2016: Deltanoid Pharmaceuticals Announces Appointment of Douglas Jermasek as Chief Executive Officer 136 Jan 19, 2016: Aurinia Announces Completion of Patient Enrollment in Its Phase 2B AURA-LV Study in Lupus Nephritis 137 Dec 03, 2015: Ocata's Hemangio-derived Mesenchymal Cells Preserve Kidney Function and Extend Lifespan in Preclinical Model of Lupus Nephritis 138 Nov 24, 2015: Aurinia Pharmaceuticals Announces Outcome from Data and Safety Monitoring Board for Its Phase 2b Study in Lupus Nephritis - Study to Continue as Planned 139 Nov 10, 2015: Kineta, Seattle Children's Research Institute Present New Data Demonstrating Positive, Predictive Responses to Dalazatide In Lupus 139 Appendix 141 Methodology 141 Coverage 141 Secondary Research 141 Primary Research 141 Expert Panel Validation 141 Contact Us 141 Disclaimer 142
List of Tables
Number of Products under Development for Lupus Nephritis, H2 2016 10 Number of Products under Development for Lupus Nephritis - Comparative Analysis, H2 2016 11 Number of Products under Development by Companies, H2 2016 13 Number of Products under Investigation by Universities/Institutes, H2 2016 14 Comparative Analysis by Late Stage Development, H2 2016 15 Comparative Analysis by Clinical Stage Development, H2 2016 16 Comparative Analysis by Early Stage Development, H2 2016 17 Products under Development by Companies, H2 2016 18 Products under Development by Companies, H2 2016 (Contd..1) 19 Products under Investigation by Universities/Institutes, H2 2016 20 Lupus Nephritis - Pipeline by AbbVie Inc, H2 2016 21 Lupus Nephritis - Pipeline by Asahi Kasei Pharma Corp., H2 2016 22 Lupus Nephritis - Pipeline by Astellas Pharma Inc., H2 2016 23 Lupus Nephritis - Pipeline by Aurinia Pharmaceuticals Inc, H2 2016 24 Lupus Nephritis - Pipeline by Azano Pharmaceuticals Inc., H2 2016 25 Lupus Nephritis - Pipeline by Boehringer Ingelheim GmbH, H2 2016 26 Lupus Nephritis - Pipeline by Bristol-Myers Squibb Company, H2 2016 27 Lupus Nephritis - Pipeline by Deltanoid Pharmaceuticals Inc., H2 2016 28 Lupus Nephritis - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 29 Lupus Nephritis - Pipeline by GlaxoSmithKline Plc, H2 2016 30 Lupus Nephritis - Pipeline by HanAll Biopharma Co., Ltd., H2 2016 31 Lupus Nephritis - Pipeline by Invion Limited, H2 2016 32 Lupus Nephritis - Pipeline by KPI Therapeutics, Inc., H2 2016 33 Lupus Nephritis - Pipeline by MedImmune, LLC, H2 2016 34 Lupus Nephritis - Pipeline by Omeros Corporation, H2 2016 35 Lupus Nephritis - Pipeline by Ra Pharmaceuticals, Inc., H2 2016 36 Lupus Nephritis - Pipeline by Resolve Therapeutics, LLC, H2 2016 37 Lupus Nephritis - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 38 Lupus Nephritis - Pipeline by TxCell SA, H2 2016 39 Assessment by Monotherapy Products, H2 2016 40 Number of Products by Stage and Target, H2 2016 42 Number of Products by Stage and Mechanism of Action, H2 2016 44 Number of Products by Stage and Route of Administration, H2 2016 46 Number of Products by Stage and Molecule Type, H2 2016 48 Lupus Nephritis - Dormant Projects, H2 2016 124 Lupus Nephritis - Dormant Projects (Contd..1), H2 2016 125 Lupus Nephritis - Discontinued Products, H2 2016 126



To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify